Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-CATH: REGN9933 and REGN7508 for Prevention of VTE in Patients With a PICC
NCT06299111Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of amrecibart, REGN7508 in venous thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals. Started Sep 2024; status: completed.
02
Drugs
amrecibartREGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06299111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299111.